# A Study of OV101 in Individuals With Fragile X Syndrome

> **NCT03697161** · PHASE2 · COMPLETED · sponsor: **Healx AI** · enrollment: 36 (actual)

## Conditions studied

- Fragile X Syndrome (FXS)

## Interventions

- **DRUG:** OV101 (gaboxadol)

## Key facts

- **NCT ID:** NCT03697161
- **Lead sponsor:** Healx AI
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-17
- **Primary completion:** 2020-02-03
- **Final completion:** 2020-02-26
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03697161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03697161, "A Study of OV101 in Individuals With Fragile X Syndrome". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03697161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*